International Spinal Cord Injury Biobank (ISCIB), Canada

Certification Status: Invite Member

Registration Status: Completed

Objective: The purpose of the International Spinal Cord Injury Biobank (ISCIB) is to facilitate investigation of the cause, development, diagnosis and treatment of spinal cord injury (SCI). Biospecimens and their associated de-identified information are made available to researchers who are conducting research that has undergone ethical review and is aimed to improve the overall understanding of SCI and the spine. All ISCIB requests must be approved by the ISCIB Operational & Scientific Access Committee before a Material Transfer Agreement is executed. Please visit www.sci-biobank.org, or email velenosi@icord.org for more information about ISCIB.

Registered Biobank Name	International Spinal Cord Injury Biobank (ISCIB)
Biobank Leader	Adam Velenosi
Country	Canada
Email for biobank inquiries	velenosi@icordi.org
Principal Investigator	Dr. Brian Kwon
Website	www.sci-biobank.org
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).